A once-weekly 2mg injection of Novo Nordisk’s Ozempic semaglutide product Ozempic has been approved for use in America, following results of the SUSTAIN FORTE trial, which showed that a higher dose of the drug led to better haemaglobin A1c control and slightly better weight loss, meaning lower risk of heart attack or stroke. However, there was a downside in terms of higher risk of gastrointestinal upsets. Two other similar forms of semaglutide Rybelsus and Wegovy, are also available, but Rybelsus is a daily pill and Wegovy at a higher once-weekly dose of 2.4mg, is only so far licensed for obesity. So far the higher Ozempic dose is not available in England but Novo Nordisk is expected to argue that an additional dosing option will give doctors and people with diabetes an additional alternative to personalise their treatment.
For more CLICK HERE
